Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

Get ready for the second wave of PD-1/L1 checkpoint inhibitors.

BeiGene $BGNE announced just ahead of the start of the week in Beijing that their PD-1 tislelizumab — partnered with Celgene $CELG — scored stellar data in a small Phase II trial for classical Hodgkin’s lymphoma among patients who had either failed or couldn’t take autologous stem cell transplantation.